Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 8/20 | 0.36 |
| ▸ | NOS3 | P29474 | 6/20 | 0.36 |
| ▸ | NOS1 | P29475 | 5/20 | 0.34 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18879258 | 0.85 | NPC1 (0.36) | NOS2NOS3NOS1RIPK2 | |
| SCHEMBL179483 | 0.80 | GAA (0.42) | NOS2NOS3NOS1 | |
| SCHEMBL18935517 | 0.76 | ESR1 (0.33) | — | |
| SCHEMBL17923118 | 0.74 | NOS3 (0.47) | NOS2NOS3NOS1 | |
| SCHEMBL19593060 | 0.70 | NPC1 (0.35) | — | |
| SCHEMBL21868839 | 0.69 | ESR1 (0.33) | — | |
| SCHEMBL21782793 | 0.69 | ALDH1A1 (0.39) | — | |
| SCHEMBL21970982 | 0.69 | CYP3A4 (0.37) | NOS2NOS3NOS1 | |
| SCHEMBL685123 | 0.69 | — | — | |
| SCHEMBL239913 | 0.68 | NOS2 (0.45) | NOS2NOS3NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230364097-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | INFINITY PHARMACEUTICALS, INC. (US) | 2023-11-16 | — | — | US | disclosed |
| US-20170360795-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | INFINITY PHARMACEUTICALS, INC. (US) | 2017-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170360795-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | PIK3CA, MCL1, PIK3CB | NOS2 4645/4885NOS3 4398/4885NOS1 4656/4885 |
| US-20230364097-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | PIK3CA, MCL1, PIK3CB | NOS2 4645/4885NOS3 4398/4885NOS1 4656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.